Erratum

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716))

P. Y. Kwo, E. J. Lawitz, J. McCone

Research output: Contribution to journalArticle

4 Citations (Scopus)
Original languageEnglish
Pages (from-to)1224
Number of pages1
JournalThe Lancet
Volume376
Issue number9748
DOIs
StatePublished - Oct 9 2010
Externally publishedYes

Fingerprint

Ribavirin
Hepatitis C
Protease Inhibitors
Genotype
Infection
Therapeutics
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
peginterferon alfa-2b

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{478f805007824cb1b01ab6df5a8db128,
title = "Erratum: Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716))",
author = "Kwo, {P. Y.} and Lawitz, {E. J.} and J. McCone",
year = "2010",
month = "10",
day = "9",
doi = "10.1016/S0140-6736(10)61881-8",
language = "English",
volume = "376",
pages = "1224",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9748",

}

TY - JOUR

T1 - Erratum

T2 - Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): An open-label, randomised, multicentre phase 2 trial (Lancet (2010) 376 (705-716))

AU - Kwo, P. Y.

AU - Lawitz, E. J.

AU - McCone, J.

PY - 2010/10/9

Y1 - 2010/10/9

UR - http://www.scopus.com/inward/record.url?scp=77957978374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957978374&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(10)61881-8

DO - 10.1016/S0140-6736(10)61881-8

M3 - Article

VL - 376

SP - 1224

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9748

ER -